Billeaud Capital Management Inc. lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 8.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,968 shares of the medical instruments supplier’s stock after selling 173 shares during the period. Becton Dickinson and makes up about 0.2% of Billeaud Capital Management Inc.’s holdings, making the stock its 26th biggest position. Billeaud Capital Management Inc.’s holdings in Becton Dickinson and were worth $443,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. IMS Capital Management acquired a new stake in Becton Dickinson and in the third quarter valued at approximately $29,000. Acropolis Investment Management LLC bought a new stake in Becton Dickinson and during the third quarter worth $101,000. Almanack Investment Partners LLC. bought a new stake in Becton Dickinson and during the second quarter worth $105,000. Truvestments Capital LLC bought a new stake in Becton Dickinson and during the third quarter worth $105,000. Finally, Bridgeworth LLC bought a new stake in Becton Dickinson and during the second quarter worth $131,000. 83.77% of the stock is owned by institutional investors and hedge funds.
BDX has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. Barclays initiated coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price target on the stock. TheStreet lowered Becton Dickinson and from a “b+” rating to a “c+” rating in a report on Friday, December 7th. UBS Group began coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price on the stock. Finally, KeyCorp boosted their target price on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday, November 8th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $251.85.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the business earned $2.40 earnings per share. The firm’s revenue was up 39.0% on a year-over-year basis. On average, research analysts anticipate that Becton Dickinson and Co will post 12.11 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, December 31st. Stockholders of record on Monday, December 10th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date was Friday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s payout ratio is 27.97%.
In other Becton Dickinson and news, EVP James W. Borzi sold 5,887 shares of the company’s stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the completion of the transaction, the executive vice president now owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. In the last three months, insiders sold 81,795 shares of company stock valued at $19,571,318. 0.12% of the stock is currently owned by corporate insiders.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: What does EPS mean?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.